Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b Study of Enpatoran in SLE and CLE
NCT04647708Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Dec 2020
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 1, randomised, double-blind trial of enpatoran in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE), sponsored by Merck KGaA. Primary endpoints: Treatment-Emergent Adverse Events at Day 186 and Number of Participants with Confirmed Signs and Symptoms of Prodromal Seizure at Day 186. Started Dec 2020; status: completed.
02
Drugs
enpatoran
03
Conditions
systemic lupus erythematosus (SLE)cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on NCT04647708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04647708.